Health Condition 1: H00-H05- Disorders of eyelid, lacrimal system and orbit
Conditions
Interventions
Intervention1: Topical bevacizumab eye drops: Topical bevacizumab 0.05% eye drops in patients with dry eye disease
Control Intervention1: standard treatment for dry eye disease: group not taking bevac
Sponsors
Dr Ankur Mishra
Eligibility
Inclusion criteria
Inclusion criteria: 1. All patients of dry eye disease 2.Chronic symptoms of burning or foreign body sensation or itching of both eyes for 12 months
Exclusion criteria
Exclusion criteria: 1.Any structural abnormalities such as eyelid trichiasis entropion and scarring 2.Use of any other topical medication other than artificial tears within the past month 3.Use of any systemic anti inflammatory drugs or medication that may interfere with tear production such as antianxiety antidepressive and antihistamine medications within 3 months 4.A history of any Bevacizumab contraindications such as heart failure gastrointestinal perforation and pregnancy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.To determine the effect of topical Bevacizumab 0.05% eye drops in patients with dry eye disease 2.To compare the outcome of topical Bevacizumab 0.05% eye drops with standard care in terms of Schirmer TBUT OSDI score.Timepoint: 12 weeks duration | — |
Secondary
| Measure | Time frame |
|---|---|
| NILTimepoint: NIL | — |
Countries
India
Contacts
Public ContactDr Ankur Mishra
Shyam shah medical college rewa
Outcome results
None listed